Physician profile
Washington Sereatan
NPI 1750351698
$7,767.88
in general payments reported to CMS, 2019-2025
29 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.71 · 2020: $1,171 · 2021: $1,285 · 2022: $1,351 · 2023: $894 · 2024: $1,334 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890 · Education: $20.22 · Travel and Lodging: $13.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,890.04 |
| Education | $20.22 |
| Travel and Lodging | $13.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $894.36 | 2020-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $829.46 | 2020-2025 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $723.68 | 2020-2025 | Vafseo, Auryxia |
| Amgen INC. | $708.76 | 2020-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $607.86 | 2021-2025 | |
| Horizon Therapeutics Plc | $511.74 | 2020-2023 | Krystexxa |
| Vifor Pharma, INC. | $426.29 | 2020-2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $370.56 | 2019-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $270.46 | 2020-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $248.00 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $234.16 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $230.75 | 2020-2024 | Velphoro |
| Ani Pharmaceuticals, INC. | $214.61 | 2024-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $197.60 | 2022-2025 | Benlysta, Shingrix, Arexvy |
| Scpharmaceuticals INC. | $192.37 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $192.24 | 2022-2025 | |
| Lilly USA, LLC | $168.56 | 2021-2025 | Jardiance, Mounjaro |
| Aurinia Pharma U.S., INC. | $163.11 | 2022-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.97 | 2024-2025 | Jardiance |
| Medtronic, INC. | $105.86 | 2021 | |
| Ardelyx, INC. | $101.18 | 2024 | Ibsrela |
| Novo Nordisk INC | $53.96 | 2024 | Rybelsus, Ozempic |
| Pharmacosmos Therapeutics INC. | $46.89 | 2022-2023 | Monoferric |
| Abbott Laboratories | $29.57 | 2024 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $28.05 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $25.58 | 2025 | Prevymis |
| Apellis Pharmaceuticals, INC. | $23.38 | 2025 | Empaveli |
| Cormedix INC. | $17.48 | 2025 | |
| Amicus Therapeutics, INC. | $17.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Washington Sereatan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.